Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes than patients receiving a standard-of-care blood thinner, a new study has ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Abelacimab shows a 62% reduction in major or clinically relevant non-major bleeding compared to rivaroxaban in AFib patients. The study highlights an 89% reduction in gastrointestinal bleeding ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Promising results show that abelacimab could revolutionize anticoagulation therapy by slashing bleeding risks without compromising stroke protection for patients with atrial fibrillation.

The published results closely match the presentation. Find our full coverage below. PHILADELPHIA, PA—The novel factor XI inhibitor abelacimab, given subcutaneously once a month, is far less likely to ...

The median reduction in free factor XI levels was 99% and 97% with abelacimab at a dose of 150mg and 90mg, respectively, at 3 months. (HealthDay News) — Subcutaneous injection of abelacimab ...